Concerning the receptor tyrosine kinase (RTK) MET, although mutations are rare in HCC and they predominantly occur in paediatric HCC [17, 18], it is activated in close to 50% of cases [19], participates in tumour-stroma crosstalk [20], and correlates with poor prognosis [21, 22]. The gene discussed is MET; the disease is hepatocellular carcinoma.